JP2025506403A5 - - Google Patents
Info
- Publication number
- JP2025506403A5 JP2025506403A5 JP2024546064A JP2024546064A JP2025506403A5 JP 2025506403 A5 JP2025506403 A5 JP 2025506403A5 JP 2024546064 A JP2024546064 A JP 2024546064A JP 2024546064 A JP2024546064 A JP 2024546064A JP 2025506403 A5 JP2025506403 A5 JP 2025506403A5
- Authority
- JP
- Japan
- Prior art keywords
- grna
- seq
- nucleic acid
- target sequence
- cas9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263306833P | 2022-02-04 | 2022-02-04 | |
| US63/306,833 | 2022-02-04 | ||
| PCT/US2023/012284 WO2023150272A2 (en) | 2022-02-04 | 2023-02-03 | Exon skipping to treat usher syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506403A JP2025506403A (ja) | 2025-03-11 |
| JP2025506403A5 true JP2025506403A5 (enExample) | 2026-02-12 |
Family
ID=87552793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024546064A Pending JP2025506403A (ja) | 2022-02-04 | 2023-02-03 | アッシャー症候群を処置するためのエクソンスキッピング |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250108129A1 (enExample) |
| EP (1) | EP4472675A4 (enExample) |
| JP (1) | JP2025506403A (enExample) |
| CN (1) | CN119325510A (enExample) |
| CA (1) | CA3250864A1 (enExample) |
| WO (1) | WO2023150272A2 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11028388B2 (en) * | 2014-03-05 | 2021-06-08 | Editas Medicine, Inc. | CRISPR/Cas-related methods and compositions for treating Usher syndrome and retinitis pigmentosa |
| EP3728595A1 (en) * | 2017-12-21 | 2020-10-28 | CRISPR Therapeutics AG | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
| EP3728594A1 (en) * | 2017-12-21 | 2020-10-28 | CRISPR Therapeutics AG | Materials and methods for treatment of usher syndrome type 2a |
| WO2021222318A1 (en) * | 2020-04-28 | 2021-11-04 | The Broad Institute, Inc. | Targeted base editing of the ush2a gene |
-
2023
- 2023-02-03 CN CN202380031655.2A patent/CN119325510A/zh active Pending
- 2023-02-03 WO PCT/US2023/012284 patent/WO2023150272A2/en not_active Ceased
- 2023-02-03 US US18/833,060 patent/US20250108129A1/en active Pending
- 2023-02-03 EP EP23750204.2A patent/EP4472675A4/en active Pending
- 2023-02-03 JP JP2024546064A patent/JP2025506403A/ja active Pending
- 2023-02-03 CA CA3250864A patent/CA3250864A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250235556A1 (en) | Gene therapy for autosomal dominant diseases | |
| JP2022546608A5 (enExample) | ||
| US20230017979A1 (en) | Compositions and methods for non-toxic conditioning | |
| CA2999500A1 (en) | Use of exonucleases to improve crispr/cas-mediated genome editing | |
| US20230201375A1 (en) | Targeted genomic integration to restore neurofibromin coding sequence in neurofibromatosis type 1 (nf1) | |
| US20210155938A1 (en) | Trans-splicing molecules | |
| CN113348247A (zh) | 基因组编辑方法与构建体 | |
| JP2022553573A5 (enExample) | ||
| US20230287428A1 (en) | Biallelic knockout of sarm1 | |
| JP2025175283A (ja) | Ａｍｄの処置のためのｈｔｒａ１調節 | |
| WO2017137493A1 (en) | Synthetic promoters and uses thereof | |
| US20230220361A1 (en) | Crispr-cas9 mediated disruption of alcam gene inhibits adhesion and trans-endothelial migration of myeloid cells | |
| WO2024069144A1 (en) | Rna editing vector | |
| CN114072518B (zh) | 用于治疗地中海贫血或镰状细胞病的方法和组合物 | |
| JP2023519101A5 (enExample) | ||
| US20220267777A1 (en) | Differential knockout of a heterozygous allele of rpe65 | |
| US20230279398A1 (en) | Treating human t-cell leukemia virus by gene editing | |
| EP3690046A2 (en) | Composition for treatment of hemophilia, comprising crispr/cas system having coagulation factor viii gene inversion correction potential | |
| US20240336939A1 (en) | Crispr induced disruption of mogs gene | |
| JP7539136B2 (ja) | ウイルスベクターによるｃａｓ９遺伝子の部位特異的導入方法 | |
| WO2026088097A1 (en) | Mutation-independent genome editing | |
| US12031149B2 (en) | Compositions and methods for promoting gene editing of CXCR4 gene | |
| WO2026032020A1 (zh) | Aav介导的rpgr x连锁视网膜变性的基因编辑治疗方法 | |
| WO2025043140A1 (en) | Methods and compositions for modifying expression of a mutant transforming growth factor beta induced (tgfbi) allele | |
| HK40075787A (en) | Gene therapy for autosomal dominant diseases |